SavedAdd your journal

Journals / Türk Oftalmoloji Dergisi / 2010 / Cilt: 40 - Sayı: 3

Intravitreal bevacizumab for diffuse diabetic macular edema: early results

Diffüz diyabetik makula ödeminde intravitreal bevacizumab enjeksiyonu: erken dönem sonuçlar

Gökhan İbrahim GÜLKILIK
Banu ASLAN
Ersin OBA
Ceylan USLU
Pages
145–150
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Visual acuities increased significantly from baseline at one week and one month after injection (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the early results of effectiveness and safety of intravitreal bevacizumab injection for diffuse diabetic macular edema.
📊
Key Findings & Data:Materials and Methods: In this randomized prospective study, 20 eyes of 14 patients who had intravitreal injection of 1.25 mg/0.05 ml bevacizumab for diffuse diabetic macular edema were evaluated.
💡
Conclusion & Impact:Visual acuities increased significantly from baseline at one week and one month after injection (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the early results of effectiveness and safety of intravitreal bevacizumab injection for diffuse diabetic macular edema. Materials and Methods: In this randomized prospective study, 20 eyes of 14 patients who had intravitreal injection of 1.25 mg/0.05 ml bevacizumab for diffuse diabetic macular edema were evaluated. Eyes with diffuse diabetic macular edema with foveal thickness greater than 350 µm as revealed by optical coherence tomography were included in the study. Changes in visual acuity and foveal thickness and complications were evaluated. Repeated-measures analysis of variance was used to compare mean values. Results: . Mean follow up period was 3±0.6 months. Mean best corrected visual acuities at baseline, 1 week and 1 month after injection were 0.28 ± 0.04, 0.37 ± 0.05, and 0.44 ± 0.05 respectively. Visual acuities increased significantly from baseline at one week and one month after injection (p

Özet

AMAÇ: Diffüz diyabetik makula ödemi tedavisinde intravitreal bevacizumab enjeksiyonunun etkinliği ve güvenirliliğinin erken dönem sonuçlarını değerlendirmek. GEREÇ ve YÖNTEM: Bu randomize prospektif çalışmada diyabete bağlı makula ödemi tedavisi için 1,25mg/0,05ml intravitreal bevacizumab enjeksiyonu uygulanan 14 hastanın 20 gözü incelendi. Çalışmaya optik koherens tomografi ölçümlerinde merkezi fovea kalınlığı 350 μm’un üzerinde olan diffüz diyabetik makula ödemi olguları alındı. Çalışmada araştırılan göstergeler görme keskinliği ve merkezi fovea kalınlığındaki değişiklikleri ve komplikasyonlar idi. Verilerin karşılaştırılmasında tekrarlayan ölçümler için Anova testi kullanıldı.BULGULAR: Ortalama takip süresi 3 ± 0,6 ay’dı.Tedavi öncesi, tedavi sonrası 1. hafta ve 1. ayda en iyi düzeltilmiş görme keskinlileri sırasıyla ortalama 0,28 ± 0,04; 0,37 ± 0,05; 0,44 ± 0,05 idi. Enjeksiyon öncesine göre enjeksiyon sonrası 1. hafta ve 1. ayda görme keskinliğindeki artış istatistiksel olarak anlamlıydı (p

🔖

Cite This Article

GÜLKILIK, G. İ., ASLAN, B., OBA, E., USLU, C. (2022). Intravitreal bevacizumab for diffuse diabetic macular edema: early results. Türk Oftalmoloji Dergisi, Cilt: 40 - Sayı: 3, 145–150. https://ajindex.com/articles/638463

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Y›ld›r›m Y, Ayata A, Ünal M, Sönmez M, Karaday› K, Gülecek O. Klasik tedaviye dirençli diffüz diabetik makula ödeminde intravitreal triamsinolon asetonid etkinli¤i. Ret-Vit. 2005;13:261-6
  2. Bresnick GH. Diabetic Maculopathy: A critical review highlighting diffuse macular edema. Ophthalmology. 1983;90:1301-17
  3. Diabetes Control and Complication Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes. N Engl J Med. 1993;329:977-86
  4. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet. 1998;352:837-53
  5. The Eye: Fundamentals and Principles of Ophthalmology, section II, USA, American Academy of Ophthalmology: LEO. 2000;68-88
  6. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, et al. Vascular endothelial growth factor-induced retinal permeability is mediated protein kiase C in vivo and supressed by an orally effective b-isoform-selective inhibitor. Diabetes. 1997;46:1473-80
  7. Tolentino MJ, Millet JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, et al. Intravenous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103:1820-28
  8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42
  9. Marshall J. The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol. 2005;32:43-7
  10. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400
  11. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherens tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-5
  12. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113:363-72
  13. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-